Thus, dysregulated Wnt signaling in the RV, secondary to pulmonary hypertension, may underlie development of RV dysfunction, and this may partly reflect an imbalance between Wnt5a and its antagonist sFRP3. The gene discussed is WNT5A; the disease is pulmonary arterial hypertension.